A modest amount of money can go a long way when it's invested in highly profitable industry leaders with sustained competitive advantages.
BOSTON, October 03, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented longer-term data on patients dosed in Parts A and B of its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). Prior to VX-880 treatment, all six patients enrolled had long-standing T1D with no endogenous insulin secretion, required
Or you could invest in commercial stage companies that might be about to enter a new phase of growth. Vertex shares have climbed this year, but considering the biotech's prospects, the shares still have plenty of room to run. Vertex Pharmaceuticals is the leader in the world of cystic fibrosis (CF) treatment, and it expects this dominance to last into at least the late 2030s.